Health Trials

An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

ConditionCastleman Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

The study is a pilot, observational, retrospective, and (italian) multicenter study.

The study will involve the collection of patient data from medical records for patients with Multicentric Castelman Disease Relapsed/Refractory who received treatment with at least one dose of siltuximab, as part of standard of care in a real-life context, from July 2016 till April 2022 in 31selected italian centres.

Eligibility criteria

Qualifiers

Histologically confirmed diagnosis of R/R MCD HIV and HHV-8 negative patients who underwent siltuximab in a real-life context from July 2016 till April 2022.

Age ≥ 18 yearsatenrollment

Signature of written informed consent (where applicable)

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Locations

12
IRCCS Azienda Ospedaliero - Universitaria di Bologna40138, BolognaBologna, Italy
Azienda Ospedaliera Sant'Anna e San Sebastiano81100, CasertaCaserta, Italy
Policlinico di Bari - Azienda Ospedaliero Universitaria Consorziale Policlinico70124, Bari Italy
Azienda Ospedaliera Universitaria Arcispedale Sant'Anna44124, Ferrara Italy

Sponsors and collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Lead sponsor

Source ClinicalTrials.gov